Karyopharm Therapeutics第三季度每股收益$（3.82）低于$（3.13）估计，销售额为4400万美元，超过4121.2万美元估计

Karyopharm Therapeutics (NASDAQ: KPTI) reported quarterly losses of $(3.82) per share which missed the analyst consensus estimate of $(3.13) by 22.04 percent. This is a 2.05 percent increase over losses of $(3.90) per share from the same period last year. The company reported quarterly sales of $44.000 million which beat the analyst consensus estimate of $41.212 million by 6.77 percent. This is a 13.45 percent increase over sales of $38.783 million the same period last year.